← Leaderboards
Michelle Mattson-Hoss
Infixion Bioscience, Inc.
$1,171,656
Attributed
$1,171,656
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $483.3K · FY2021–23$500K$375K$250K$125K$0
'21
'22
'23
Funding mix
By agency
NIH$1,171,656 · 2
By mechanism
R43$1,171,656 · 2
Top collaborators
No co-investigators on record.
Most similar at Infixion Bioscience, Inc.
Same institution · by research overlap
- Clifford Dustin Rubinstein$278,050
- Herb Sarnoff$278,050
Others in their field
Other Emerging Leaders on “Mek Inhibition”
- Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai$5,543,909
- Iwei Yeh · University Of California, San Francisco$3,072,504
- Elliot Stieglitz · University Of California, San Francisco$2,677,641
- Lawrence Kwong · University Of Tx Md Anderson Can Ctr$2,526,118
- Rona Yaeger · Sloan-Kettering Inst Can Research$2,512,582
- Kirsten L Bryant · Univ Of North Carolina Chapel Hill$2,507,540
Research focus
Mek InhibitionProgramsGenesIn VivoNeurofibromatosesOther GeneticsEvaluationFrap1 GeneGenetic DiseasesIn VitroDrug DiscoveryMutationNeurofibromatosis 1Dominant Genetic ConditionsDna Sequence AlterationElk1 GeneComplexFibroblastsCell ProliferationCellsCell TypeInduced Pluripotent Stem CellAssociated SymptomProtein Expression
Grant awards (7)
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency$154,078
R43 · FY2023 · NS · contact PI
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency$100,465
R43 · FY2023 · NS · contact PI
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency$56,254
R43 · FY2023 · NS · contact PI
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency$38,836
R43 · FY2023 · NS · contact PI
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency$339,520
R43 · FY2022 · NS · contact PI
Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency$143,781
R43 · FY2022 · NS · contact PI
Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency$338,722
R43 · FY2021 · NS · contact PI